Acceleron Announces Pricing of Public Offering of Common Stock
16 Enero 2019 - 6:00AM
Business Wire
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading
biopharmaceutical company in the discovery and development of
TGF-beta superfamily therapeutics intended to treat serious and
rare hematologic, neuromuscular, and pulmonary diseases, today
announced that it has priced an underwritten public offering of
5,348,838 shares of common stock at a price to the public of $43.00
per share for gross proceeds of $230.0 million. In connection with
this offering, Acceleron has granted the underwriters a 30-day
option to purchase up to an additional 802,325 shares of common
stock.
Citigroup, J.P. Morgan and SVB Leerink are acting as joint
book-runners for the offering. UBS Investment Bank is acting as
lead manager for the offering. The offering is expected to close on
or about January 18, 2019, subject to the satisfaction of customary
closing conditions.
Acceleron expects to receive net proceeds from the offering
after deducting underwriting discounts and commissions and
estimated offering expenses payable by the company of approximately
$215.8 million. Acceleron intends to use the net proceeds from the
offering to conduct clinical trials and associated activities with
therapeutic candidates from its existing research pipeline and for
general and administrative expenses (including personnel-related
costs), potential future development programs, capital expenditures
and working capital and other general corporate purposes, including
potential acquisitions of rights to additional programs from third
parties.
The shares are being offered by Acceleron pursuant to an
effective shelf registration statement on Form S-3 that was
previously filed with the Securities and Exchange Commission (the
“SEC”). A preliminary prospectus supplement relating to and
describing the terms of the offering was filed with the SEC on
January 14, 2019. The final prospectus supplement relating to the
offering will be filed with the SEC. When available, copies of the
final prospectus supplement and the accompanying prospectus can be
obtained at the SEC’s website http://www.sec.gov or from Citigroup
Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717 or telephone: 1-800-831-9146;
J.P. Morgan Securities LLC, Attention: Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone:
1-866-803-9204 or email: prospectus-eq_fi@jpmchase.com; and SVB
Leerink LLC, Attention: Syndicate Department, One Federal Street,
37th Floor, Boston, MA, 02110, by e-mail at syndicate@leerink.com,
or by phone at 800-808-7525, ext. 6132.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities in the offering, nor
shall there be any sale of these securities in any jurisdiction in
which an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such
jurisdiction.
About Acceleron
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical
company dedicated to the discovery, development, and
commercialization of therapeutics to treat serious and rare
diseases. The Company's leadership in the understanding of TGF-beta
biology and protein engineering generates innovative compounds that
engage the body's ability to regulate cellular growth and
repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Celgene, are
developing luspatercept for the treatment of chronic anemia in
myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
Acceleron is also advancing its neuromuscular franchise with two
distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2
pulmonary program with sotatercept in pulmonary arterial
hypertension.
Cautionary Note on Forward-Looking Statements
Certain statements contained in this release, including those
relating to the use of proceeds from the sale of common stock and
the expected closing of the offering, are forward-looking
statements that involve a number of risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties associated with the
consummation of the proposed offering and general economic
conditions and other risks identified from time to time in the
reports we file with the SEC, including our Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form
8-K, which are available at www.sec.gov. We caution investors not
to place considerable reliance on the forward-looking statements
contained in this press release. The forward-looking statements in
this press release speak only as of the date of this document, and
we undertake no obligation to update or revise any of the
statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190116005231/en/
Investors:Acceleron PharmaTodd James, (617) 649-9393Vice
President, Investor Relations and Corporate
CommunicationsMedia:Matt Fearer, (617) 301-9557Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024